Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.57 |
| ▸ | PGK2 | P07205 | 1/20 | 0.57 |
| ▸ | PGD | P52209 | 5/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | TPI1 | P60174 | 1/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404352 | 1.00 | PGK1 (0.57) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL30852238 | 1.00 | PGK1 (0.57) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL31657225 | 0.98 | PGK1 (0.55) | PGK1PGK2PGDMPILAP3 | |
| Phosphoric Acid SCHEMBL5917775 | 0.98 | PGK1 (0.55) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL3488353 | 0.89 | PGK1 (0.45) | PGK1PGK2PGDLAP3 | |
| SCHEMBL13176646 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL186958 | 0.84 | PGK1 (0.50) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL4867885 | 0.82 | PGK1 (0.44) | PGK1PGK2PGDMPILAP3 | |
| SCHEMBL7756355 | 0.81 | PGK1 (0.47) | PGK1PGK2PGDLAP3LPAR6 | |
| SCHEMBL14464207 | 0.78 | LAP3 (0.41) | PGK1PGK2PGDLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2919 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069577-A1 | METHODS FOR IMPROVING EXERCISE PERFORMANCE AND ENDURANCE THEREOF | NANJING NUTRABUILDING BIO TECH CO LTD (CN) | 2026-03-12 | — | — | US | claimed |
| US-20250387386-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS INC (US) | 2025-12-25 | — | — | US | claimed |
| US-12496294-B2 | Methods for improving exercise performance and endurance thereof | NANJING NUTRABUILDING BIO-TECH CO., LTD. (CN) | 2025-12-16 | — | — | US | claimed |
| US-20250332161-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4623991-A2 | METHODS FOR THE STORAGE OF WHOLE BLOOD, AND COMPOSITIONS THEREOF | Hemanext Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250276046-A1 | SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS | KaloCyte (US) | 2025-09-04 | — | — | US | claimed |
| EP-4605521-A2 | GENETICALLY MODIFIED HOST CELLS PRODUCING L-SERINE | CysBio ApS (DK) | 2025-08-27 | — | — | EP | claimed |
| EP-4591711-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | Albert Einstein College of Medicine (US) | 2025-07-30 | — | — | EP | claimed |
| EP-3297641-B1 | METHODS FOR THE STORAGE OF WHOLE BLOOD, AND COMPOSITIONS THEREOF | HEMANEXT INC (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2025104134-A9 | EXPRESSION OF BIOMOLECULES WITH IMPROVED PROMOTER AND TIR | CYSBIO APS (DK) | 2025-06-19 | — | — | WO | claimed |
| US-4738952-A | Substitute for human blood and a method of making the same | SYNTHETIC BLOOD CORPORATION (US) | 1988-04-19 | — | — | US | claimed |
| EP-0195558-A2 | Composition of alpha-alpha- cross-linked hemoglobins | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-09-24 | — | — | EP | claimed |
| US-4600531-A | DEOXYGENATION;2,3-DIPHOSPHOGLYCERATE, INOSITOL HEXAPHOSPHATE, INOSITOL HEXASULFATE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-07-15 | — | — | US | claimed |
| US-4598064-A | Alpha-alpha cross-linked hemoglobins | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1986-07-01 | — | — | US | claimed |
| EP-0179879-A1 | A SUBSTITUTE FOR HUMAN BLOOD AND A METHOD OF MAKING THE SAME | SYNTHETIC BLOOD CORPORATION (US) | 1986-05-07 | — | — | EP | claimed |
| US-4569836-A | Cancer treatment by intracellular hyperthermia | GORDON, DAVID, SKOKIE, ILLINOIS | 1986-02-11 | — | — | US | claimed |
| WO-1985005035-A1 | A SUBSTITUTE FOR HUMAN BLOOD AND A METHOD OF MAKING THE SAME | NEOMED, INC. (US) | 1985-11-21 | — | — | WO | claimed |
| EP-0077515-B1 | METHOD AND COMPOSITION FOR DETERMINING GLYCOSYLATED HEMOGLOBIN | Roche Diagnostics GmbH (DE) | 1985-03-20 | — | — | EP | claimed |
| US-4438204-A | Determination of glycosilated hemoglobin | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | claimed |
| US-4216211-A | INCREASES LEVEL OF 2,3-DIPHOSPHOGLYCERATES IN THE BLOOD | THE PROCTER & GAMBLE COMPANY (US) | 1980-08-05 | — | — | US | claimed |